As Fiona Marshall makes her move to NIBR, Merck is ready with a key replacement player
Just hours after Novartis flagged a big change at the top of NIBR — with Jay Bradner exiting and offering his post on the executive committee to Merck’s Fiona Marshall — Merck was ready with a switch as well.
The new SVP in charge of discovery, preclinical and translational work at Merck is George Addona, a company vet who first came on board in 2008. Addona’s most recent post involved adopting new technologies to help identify the best early-stage programs. And before that, he had played a leading role in creating the chemical biology group at Merck Research Labs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
